FDA committee gives push forward for Aerie’s Rhopressa

The FDA’s Dermatologic and Ophthalmic Drugs Advisory Committee voted favorably on questions of efficacy regarding Aerie Pharmaceuticals’ glaucoma drug Rhopressa.
Rhopressa (netarsudil ophthalmic solution 0.02%) is a once-daily eye drop designed to lower IOP in patients with open-angle glaucoma or ocular hypertension by targeting the trabecular meshwork.
The panel voted 10 yes, zero no and zero abstentions on the following question: Do the clinical trials support the efficacy of netarsudil ophthalmic solution for reducing elevated intraocular pressure in patients with open-angle

Full Story →